KIN Kindred Biosciences, Inc. gains 20% Jul 10, 2017

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates include Zimeta, a pyrazolone anti-inflammatory drug, for the treatment of fever in horses; and KIND-010 for management of weight loss in cats and feline epo for anemia in cats. The company's other small molecule product candidates consist of KIND-014 for treatment of equine gastric ulcer syndrome; and KIND-015 for the treatment of metabolic syndrome in horses. It is also developing biologics products, such as KIND-510, a feline erythropoeitin for treatment of anemia in cats; KIND-502 for the treatment of allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; and KIND-509, an antibody that targets the canine TNF. The company was founded in 2012 and is headquartered in Burlingame, California. http://www.priceseries.com/trade/KIN-Kindred-Biosciences-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2017062020170710.html